OVC.2
NCT02502266
OVC.2
A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Status:
Closed to Accrual
II/III
Phase
2nd+
Line of Therapy
Relapsed / Recurrent / Refractory
Disease Stage
Biomarker(s)
BRCA1/2
Investigational
Product
Olaparib + Cediranib Maleate
Treatment Arms
o Active Comparator: Phase II Arm I
o Experimental: Phase II Arm II (cediranib maleate, olaparib)
o Experimental: Phase II Arm III (cediranib maleate)
o Experimental: Phase II Arm IV (olaparib)
o Active Comparator: Phase III Arm I (reference regimen)
o Experimental: Phase III Arm II (cediranib maleate, olaparib)
o Experimental: Phase III Arm III (single-agent cediranib maleate)